Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 207

Sort by

Sort Order Select

Journal Articles

A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle

Xuejie Chen, Caihong Li, Da-Yun Jin, Brian Ingram, Zhenyu Hao, Xue Bai, Darrel W. Stafford, Keping Hu, Jian-Ke Tie

Blood (2020) 136 (7): 898–908.

https://doi.org/10.1182/blood.2019004234

Published: 2020

Includes: Supplemental data

Journal Articles

Vitamin K therapy to reduce bleeding

Mettine H. A. Bos, Felix J. M. van der Meer

Blood (2020) 136 (7): 780–782.

https://doi.org/10.1182/blood.2020006563

Published: 2020

Journal Articles

Structural Basis of Vitamin K Antagonism

Weikai Li, PhD, Shixuan Liu, Shuang Li

Blood (2019) 134 (Supplement_1): 482.

https://doi.org/10.1182/blood-2019-127324

Published: 2019

Journal Articles

Comparison of New Oral Anticoagulants (NOAC) Based Double Therapy Versus Vitamin K Antagonist Based Triple Therapy in Patients Undergoing Percutaneous Coronary Intervention with Atrial Fibrillation: A Systematic Review and Meta-Analysis

Muhammad Zain Farooq, MD MBBS, Prasanth Lingamaneni, Muhammad Saad Farooq, MBBS, Aakash Putta, MD MBBS, Sheeba Ba Aqeel, VV Pavan Kedar Mukthinuthalapati, Ankit Mangla, MBBS, MD, Paul Rubinstein, MD

Blood (2019) 134 (Supplement_1): 4963.

https://doi.org/10.1182/blood-2019-129607

Published: 2019

Journal Articles

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Shveta Gupta, MBBS, Ayesha Zia, MD, Ravindra Sarode, MD

Blood (2019) 134 (Supplement_1): 4976.

https://doi.org/10.1182/blood-2019-129118

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Evaluation of a Fixed, Low-Dose Four-Factor Prothrombin Complex Concentrate Dosing Protocol for International Normalized Ratio Reversal at Two Academic Medical Centers

Kathryn Dane, PharmD, John Lindsley, PharmD, Satish Pramod Shanbhag, MBBS, MPH, Michael B. Streiff, MD

Blood (2019) 134 (Supplement_1): 3386.

https://doi.org/10.1182/blood-2019-131404

Published: 2019

Journal Articles

Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis

Blood (2019) 134 (3): 227–238.

https://doi.org/10.1182/blood.2018874214

Published: 2019

Includes: Supplemental data

Journal Articles

Bad weed: synthetic cannabinoid–associated coagulopathy

Gowthami M. Arepally, Thomas L. Ortel

Blood (2019) 133 (9): 902–905.

https://doi.org/10.1182/blood-2018-11-876839

Published: 2019

Journal Articles

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Lorraine Cafuir, MD, En Cheng, Christine L Kempton, MD MSc

Blood (2018) 132 (Supplement 1): 826.

https://doi.org/10.1182/blood-2018-99-110685

Published: 2018

Journal Articles

Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients

Graham McIlroy, MD, Neil Smith, MD FRCPath, Anand Lokare, MD FRCPath, MRCP, Karen Beale, Charalampos Kartsios, MD

Blood (2018) 132 (Supplement 1): 5058.

https://doi.org/10.1182/blood-2018-99-111108

Published: 2018

Journal Articles

Saskatoon Urban Hospital Frozen Plasma Utilization and Appropriateness Audit

Jennifer E Leung, MD, Heather Panchuk, Oksana C. Prokopchuk-Gauk, MDBSc

Blood (2018) 132 (Supplement 1): 5074.

https://doi.org/10.1182/blood-2018-99-114176

Published: 2018

Journal Articles

Efficacy and Safety of Prothrombin Complex Concentrate in Patients Treated with Rivaroxaban or Apixaban Compared to Warfarin Presenting with Major Bleeding

Deepa Jayakody Arachchillage, MD MRCP, FRCPath, Sharon Alavian, Jessica Griffin, MRCP, Kamala Gurung, MRCP, Richard Syzdlo, PhD, Nilanthi Karawitage, Michael Laffan, DM, FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 2535.

https://doi.org/10.1182/blood-2018-99-116432

Published: 2018

Journal Articles

Inpatient Mortality and Length of Stay Among Direct-Acting Oral Anticoagulant (DOAC) and Warfarin Users Presenting with Major Hemorrhage

Walter Bialkowski, PhD MS, Sylvia Tan, MS, Alan E. Mast, MDPhD, Joseph Kiss, MD, Daryl J. Kor, MD MSc, Jerome Gottschall, MD, Yanyun Wu, MD PhD, Nareg H. Roubinian, MD, Darrell Triulzi, MD, Steven Kleinman, MD, Young Choi, MD, Donald Brambilla, PhD, Ann Butler Zimrin, MD, The NHLBI Recipient Epidemiology and Donor Evaluation Study-III

Blood (2018) 132 (Supplement 1): 2538.

https://doi.org/10.1182/blood-2018-99-112631

Published: 2018

Journal Articles

Analysis of the Safety Profile of Commonly Used Procoagulants Using the FDA Adverse Event Reporting System

Emma P. Deloughery, BS, Joseph J. Shatzel, MD

Blood (2018) 132 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2018-99-109822

Published: 2018

Journal Articles

Vitamin K epoxide reductase: moving closer to nature

Martin J. Shearer

Blood (2018) 132 (18): 1867–1869.

https://doi.org/10.1182/blood-2018-08-869578

Published: 2018

Journal Articles

Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu

Xuejie Chen, Da-Yun Jin, Darrel W. Stafford, Jian-Ke Tie

Blood (2018) 132 (18): 1974–1984.

https://doi.org/10.1182/blood-2018-05-846592

Published: 2018

Includes: Supplemental data

Journal Articles

Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition

Sangwook Wu, Xuejie Chen, Da-Yun Jin, Darrel W. Stafford, Lee G. Pedersen, Jian-Ke Tie

Blood (2018) 132 (6): 647–657.

https://doi.org/10.1182/blood-2018-01-830901

Published: 2018

Includes: Multimedia, Supplemental data

Journal Articles

Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase

Mark A. Rishavy, Kevin W. Hallgren, Lee Wilson, Savita Singh, Kurt W. Runge, Kathleen L. Berkner

Blood (2018) 131 (25): 2826–2835.

https://doi.org/10.1182/blood-2017-09-804666

Published: 2018

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Direct-Acting Oral Anticoagulation (DOACs) Based on BMI

Kimberley Doucette, Bhavisha Patel, MD, Anusha Vakiti, Kelly W. Fitzpatrick, MD

Blood (2017) 130 (Supplement 1): 3715.

https://doi.org/10.1182/blood.V130.Suppl_1.3715.3715

Published: 2017

NARROW

A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle

Vitamin K therapy to reduce bleeding

Structural Basis of Vitamin K Antagonism

Comparison of New Oral Anticoagulants (NOAC) Based Double Therapy Versus Vitamin K Antagonist Based Triple Therapy in Patients Undergoing Percutaneous Coronary Intervention with Atrial Fibrillation: A Systematic Review and Meta-Analysis

International Survey for Strategies Used for Oral Anticoagulation Reversal in Children

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Evaluation of a Fixed, Low-Dose Four-Factor Prothrombin Complex Concentrate Dosing Protocol for International Normalized Ratio Reversal at Two Academic Medical Centers

Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis

Bad weed: synthetic cannabinoid–associated coagulopathy

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Treatment Failure in Patients Receiving Direct Oral Anticoagulants: Clinical Management and Outcomes from a Single-Center Review of 59 Consecutive Patients

Saskatoon Urban Hospital Frozen Plasma Utilization and Appropriateness Audit

Efficacy and Safety of Prothrombin Complex Concentrate in Patients Treated with Rivaroxaban or Apixaban Compared to Warfarin Presenting with Major Bleeding

Inpatient Mortality and Length of Stay Among Direct-Acting Oral Anticoagulant (DOAC) and Warfarin Users Presenting with Major Hemorrhage

Analysis of the Safety Profile of Commonly Used Procoagulants Using the FDA Adverse Event Reporting System

Vitamin K epoxide reductase: moving closer to nature

Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu

Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition

Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase

Safety and Efficacy of Direct-Acting Oral Anticoagulation (DOACs) Based on BMI

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only